Core Viewpoint - The company Yi Sheng Biotechnology (01061) has entered into an exclusive distribution agreement with Osteopore International Pte Ltd, a leader in 3D printed biomimetic and bioresorbable implants, to distribute innovative dental, orthodontic, and maxillofacial products in mainland China, Hong Kong, and Macau [1] Group 1 - The agreement is valued at over RMB 12 million, which includes advance payments and milestone payments, with potential for additional revenue through product procurement and supply [1] - The collaboration with Osteopore marks a significant milestone for the company in the oral market and expands its product line in dental, orthodontic, and maxillofacial solutions [1] - This partnership is expected to support the company's pursuit of sustainable growth in the Chinese market [1]
亿胜生物科技与OSTEOPORE订立独家分销协议